46 results
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
15 Mar 22
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results
7:31am
-cell lymphomas.
Advanced the company’s NAM-enabled natural killer (NK) cell pipeline, including targets GDA-301, GDA-501 and GDA-601, which focus … on solid-tumor and hematological cancers. These targets utilize CAR, membrane bound- and CRISPR-mediated technologies to increase targeting, potency
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
10 May 22
Gamida Cell Reports First Quarter 2022 Financial Results
7:30am
preclinical proof of concept studies for these genetically modified NK therapeutic targets and to select a product candidate for IND enabling studies … by the end of 2022. These therapeutic targets include:
GDA-301: Knockout of CISH (cytokine inducible SH2 containing protein) in NK cells using CRISPR
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
15 Aug 22
Gamida Cell Reports Second Quarter 2022 Financial Results
7:15am
. The company continues to conduct in vitro and in vivo preclinical proof-of-concept studies for these genetically modified NK therapeutic targets which … . These therapeutic targets include:
GDA-301: Knockout of CISH (cytokine inducible SH2 containing protein) in NK cells using CRISPR/Cas9 in combination
6-K
EX-99.1
GMDAQ
Gamida Cell Ltd
19 Feb 19
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
2:05pm
Medicine will engage in joint research to evaluate unnamed targets by combining Gamida Cell’s proprietary NAM-based cell expansion technology with Editas
6-K
GMDAQ
Gamida Cell Ltd
13 Jan 20
Gamida Cell Announces 2020 Goals and Provides Company Update
5:00pm
a press release (the “Press Release”) announcing its 2020-2021 goals and providing a company update.
Expected 2020-2021 Milestones.
The Company targets
8-K
EX-99.1
agr4e0eyvlwl776pb
31 Jan 22
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
9:00am
6-K
EX-99.1
8x7 uvq0tlngh1
13 Jan 20
Gamida Cell Announces 2020 Goals and Provides Company Update
5:00pm
6-K
EX-99.1
4v5isjz
25 Feb 20
Gamida Cell Reports Full Year 2019 Financial Results and Provides Company Update
5:08pm
6-K
EX-99.1
jnixys7frgjjyij386o5
21 May 20
Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update
8:40am
8-K/A
EX-99.1
qnj2x3pa9ahd6
10 May 24
Other Events
4:19pm
6-K
EX-99.1
b6wog2
15 Nov 21
Gamida Cell Reports Third Quarter 2021 Financial Results
7:29am
8-K
EX-99.1
nyqc1uf81g7nuxl7a
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
F-1
EX-10.13
aeayg0q0drz73ai48477
24 Jun 19
Registration statement (foreign)
4:04pm
20-F
EX-4.13
1o8 fqzvxw4x9ji
25 Feb 19
Annual report (foreign)
5:08pm
8-K/A
EX-99.1
dkcydm3 to10os3
28 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:47pm